New gene therapy injected into eye aims to halt rare vision loss
NCT ID NCT07161544
Summary
This study is testing a new gene therapy, AAVB-039, for people with Stargardt disease, a genetic condition that causes vision loss. The main goal is to see if a single injection into the back of the eye is safe. Researchers will also check if the treatment can slow or stop the progression of the disease by measuring changes in vision and eye structure.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STARGARDT DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Moorfields Eye Hospital NHS Foundation Trust
RECRUITINGLondon, England, EC1V 2PD, United Kingdom
-
Retina Consultants of Texas
RECRUITINGBellaire, Texas, 77401, United States
-
Retina Foundation of the Southwest
RECRUITINGDallas, Texas, 75231, United States
Contact Email: •••••@•••••
-
The Retina Clinic
RECRUITINGLondon, England, W1G 9AX, United Kingdom
Conditions
Explore the condition pages connected to this study.